Anti-PD1 antibody [EPR4877(2)] (Ab137132)

CD279, PD1, PDCD1, Programmed cell death protein 1, Protein PD-1, hPD-1

反应种属:Human
抗原名称:PDCD1
应用:IHC

详细信息

免疫原The exact immunogen used to generate this antibody is proprietary information.
宿主/亚型Rabbit / IgG
抗体类型Monoclonal
产品形式Liquid
纯化方式Affinity purification Protein A
储存缓冲液Preservative: 0.01% Sodium azide Constituents: PBS, 40% Glycerol (glycerin, glycerine), 0.05% BSA
储存条件运输条件: Conditional Ambient 推荐的短期储存时间: 1-2 weeks 推荐的短期储存条件: +4°C 推荐的长期储存条件: -20°C 储存信息: Avoid freeze / thaw cycle
无载体蛋白No

背景信息

Anti-PD1 antibody [EPR4877(2)] (ab137132) was developed by Abcam using patented rabbit monoclonal antibody technology and is validated for use in IHC-P. Anti-PD1 antibody [EPR4877(2)] (ab137132) was first used in a scientific publication in 2014 and has been cited over 101 times in peer reviewed journals. It's performance in IHC in human samples is trusted by the scientific community. Abcam's high quality manufacturing and validation processes ensure Anti-PD1 antibody [EPR4877(2)] (ab137132) has high sensitivity and specificity alongside high lot-to-lot consistency and reproducibility. Anti-PD1 antibody [EPR4877(2)] (ab137132) has 5 independent reviews from customers. Anti-PD1 antibody [EPR4877(2)] (ab137132) specifically detects PD1 (UniProt ID: Q15116; Molecular weight: 29kDa) and is sold in a convenient trial size to enable initial testing (20 µL) and larger sizes for subsequent scaling up experiments (100 µL and 1 mL). Conjugation-ready, carrier free format available for antibody clone EPR4877(2) - ab186928. Antibody clone EPR4877(2) is also available pre-conjugated to a variety of labels for your convenience - Alexa Fluor ® 647, Alexa Fluor ® 555, Alexa Fluor ® 594, Alexa Fluor ® 488, Alexa Fluor ® 568, Alexa Fluor ® 750 ( ab201825, ab275126, ab275349, ab311022, ab313074, ab321110 ). PD-1 is an immune checkpoint receptor that, when engaged by its ligands PD-L1 or PD-L2, inhibits T-cell activity, allowing tumors to evade immune detection. Blocking the PD-1 pathway with immune checkpoint inhibitors reactivates T-cells, enhancing the immune system's ability to target and destroy cancer cells. Species reactivity Mouse, Rat: We have preliminary internal testing data to indicate this antibody may not react with these species. Please contact us for more information. Patented technology Our RabMAb ® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb ® patents. What are the advantages of a recombinant monoclonal antibody? This product is a recombinant monoclonal antibody, which offers several advantages including - High batch-to-batch consistency and reproducibility - Improved sensitivity and specificity - Long-term security of supply - Animal-free batch production For more information, read more on recombinant antibodies.

文献引用 (118)

Cancer-induced nerve injury promotes resistance to anti-PD-1 therapy

癌症引起的神经损伤会促进对PD-1抑制剂的耐药性

Erez N Baruch # ,Frederico O Gleber-Netto # ,Priyadharsini Nagarajan # ,Xiayu Rao # ,Shamima Akhter # ,Tuany Eichwald # ,Tongxin Xie ,Mohammad Balood ,Adebayo Adewale ,Shorook Naara ,Hinduja N Sathishkumar ,Shajedul Islam ,William McCarthy ,Brandi J Mattson ,Renata Ferrarotto ,Michael K Wong ,Michael A Davies ,Sonali Jindal ,Sreyashi Basu ,Karine Roversi ,Amin Reza Nikpoor ,Maryam Ahmadi ,Ali Ahmadi ,Catherine Harwood ,Irene Leigh ,Dennis Gong ,Paulino Tallón de Lara ,Derrick L Tao ,Tara M Davidson ,Nadim J Ajami ,Andrew Futreal ,Kunal Rai ,Veena Kochat ,Micah Castillo ,Preethi Gunaratne ,Ryan P Goepfert ,Sharia D Hernandez ,Nikhil I Khushalani ,Jing Wang ,Stephanie S Watowich ,George A Calin ,Michael R Migden ,Mona Yuan ,Naijiang Liu ,Yi Ye ,William L Hwang ,Paola D Vermeer ,Nisha J D'Silva ,Yuri L Bunimovich ,Dan Yaniv ,Jared K Burks ,Javier Gomez ,Patrick M Dougherty ,Kenneth Y Tsai ,James P Allison ,Padmanee Sharma ,Jennifer A Wargo ,Jeffrey N Myers ,Sebastien Talbot ,Neil D Gross ,Moran Amit

Genomic mediators of acquired resistance to immunotherapy in metastatic melanoma

转移性黑色素瘤获得性免疫治疗耐药的基因组介质

Julia Schiantarelli,Mouadh Benamar,Jihye Park,Haley E Sax,Giacomo Oliveira,Alice Bosma-Moody,Katie M Campbell,David Liu,Douglas B Johnson,Scott Rodig,Catherine J Wu,F Stephen Hodi,Antoni Ribas,Eliezer Van Allen,Rizwan Haq

Distinct CD8+ T cell dynamics associate with response to neoadjuvant cancer immunotherapies

独特的CD8+ T细胞动态变化与新辅助癌症免疫疗法的疗效相关

Housaiyin Li ,Dan P Zandberg ,Aditi Kulkarni ,Simion I Chiosea ,Patricia M Santos ,Brian R Isett ,Marion Joy ,Gabriel L Sica ,Kevin J Contrera ,Curtis M Tatsuoka ,Matthias Brand ,Umamaheswar Duvvuri ,Seungwon Kim ,Mark Kubik ,Shaum Sridharan ,Fei Tu ,Jie Chen ,Tullia C Bruno ,Dario A A Vignali ,Anthony R Cillo ,Riyue Bao ,Jing Hong Wang ,Lazar Vujanovic ,Robert L Ferris

A cellular and spatial atlas of TP53-associated tissue remodeling defines a multicellular tumor ecosystem in lung adenocarcinoma.

TP53 相关组织重塑的细胞和空间图谱定义了肺腺癌中的多细胞肿瘤生态系统。

Zhao William, Nguyen Thinh T, Bhagwat Atharva, Kumar Akhil, Giotti Bruno, Kepecs Benjamin, Weirather Jason L, Mahadevan Navin R, Segerstolpe Asa, Dolasia Komal, Abdul-Ghafar Jamshid, Besson Naomi R, Jones Stephanie M, Soong Brian Y, Li Chendi, Vigneau Sebastien, Slyper Michal, Wakiro Isaac, Su Mei-Ju, Helvie Karla, Frangieh Allison, Jane-Valbuena Judit, Ashenberg Orr, Awad Mark, Rotem Asaf, Bueno Raphael, Rozenblatt-Rosen Orit, Pfaff Kathleen, Rodig Scott, Hata Aaron N, Regev Aviv, Johnson Bruce E, Tsankov Alexander M

Atezolizumab following definitive chemoradiotherapy in patients with unresectable locally advanced esophageal squamous cell carcinoma - a multicenter phase 2 trial (EPOC1802).

在无法切除的局部晚期食管鳞状细胞癌患者中,接受根治性放化疗后使用阿特珠单抗治疗——一项多中心 2 期试验 (EPOC1802)

Bando Hideaki, Kumagai Shogo, Kotani Daisuke, Mishima Saori, Irie Takuma, Itahashi Kota, Tanaka Yosuke, Habu Takumi, Fukaya Sayuri, Kondo Masaki, Tsushima Takahiro, Hara Hiroki, Kadowaki Shigenori, Kato Ken, Chin Keisho, Yamaguchi Kensei, Kageyama Shun-Ichiro, Hojo Hidehiro, Nakamura Masaki, Tachibana Hidenobu, Wakabayashi Masashi, Fukui Makoto, Fuse Nozomu, Koyama Shohei, Mano Hiroyuki, Nishikawa Hiroyoshi, Shitara Kohei, Yoshino Takayuki, Kojima Takashi

Cell populations in human breast cancers are molecularly and biologically distinct with age.

人类乳腺癌细胞群在分子和生物学上随年龄而变化。

Parsons Adrienne, Sauras Colón Esther, Manjunath Meghana, Zhang Hanyun, Chen Julia, Spasic Milos, Koca Beyza, Binboga Kurt Busem, Freedman Rachel A, Mittendorf Elizabeth A, Swarbrick Alexander, van Galen Peter, McAllister Sandra S

Spatial mapping of immune cell environments in NF2-related schwannomatosis vestibular schwannoma

NF2相关神经鞘瘤病前庭神经鞘瘤中免疫细胞环境的空间分布图谱

Adam P Jones # ,Michael J Haley # ,Miriam H Meadows ,Grace E Gregory ,Cathal J Hannan ,Ana K Simmons ,Leoma D Bere ,Daniel G Lewis ,Pedro Oliveira ,Miriam J Smith ,Andrew T King ,D Gareth R Evans ,Pawel Paszek ,David Brough ,Omar N Pathmanaban ,Kevin N Couper

Pembrolizumab plus chemotherapy in frontline treatment of advanced ovarian cancer: Clinical and translational results from a phase 2 trial

帕博利珠单抗联合化疗一线治疗晚期卵巢癌:一项 II 期试验的临床和转化结果

Jeffrey A How ,Minghao Dang ,Sanghoon Lee ,Bryan Fellman ,Shannon N Westin ,Anil K Sood ,Nicole D Fleming ,Aaron Shafer ,Ying Yuan ,Jinsong Liu ,Li Zhao ,Joseph Celestino ,Richard Hajek ,Margaret B Morgan ,Edwin R Parra ,Caddie D Laberiano Fernandez ,Claudio A Arrechedera ,Luisa Maren Solis Soto ,Kathleen M Schmeler ,Alpa Nick ,Karen H Lu ,Robert Coleman ,Linghua Wang ,Amir A Jazaeri

Therapeutic stress triggers tumor STAT1 acetylation to disarm immunotherapy

治疗应激触发肿瘤STAT1乙酰化,从而削弱免疫疗法

Po-Hsien Chiu ,Kuan-Chen Lai ,Hung-Ling Wang ,Yao-Wen Chang ,Wen-Chi Wu ,Tien-Hua Chen ,Yu-Shuen Tsai ,Jie-Hong Song ,Nai-Yun Sun ,Gar-Yang Chau ,Wen-Liang Fang ,Ju-Pei Chen ,Hung-Ming Wang ,Huai-Cheng Huang ,Meng-Che Hsieh ,Chun-Hung Hua ,Ming-Yu Lien ,Yi-Fang Chang ,Hui-Ching Wang ,Chih-Yen Chien ,Tai-Lin Huang ,Chen-Chi Wang ,Yi-Chun Liu ,Jo-Pai Chen ,Wei-Chen Lu ,Ching-Yi Yiu ,Chien-Liang Lin ,Pei-Jen Lou ,Pen-Yuan Chu ,Shao-Chun Wang ,Mien-Chie Hung ,Muh-Hwa Yang

PD-L1 phenotype classification based on expression in tumor and immune cells as a potential biomarker for optimizing anti-PD-1/CTLA-4 immunotherapies in NSCLC.

基于肿瘤细胞和免疫细胞中表达的 PD-L1 表型分类作为优化 NSCLC 中抗 PD-1/CTLA-4 免疫疗法的潜在生物标志物。

Miyakoshi Jun, Yoshida Tatsuya, Uehara Yuji, Takeyasu Yuki, Shirasawa Masayuki, Fukuda Akito, Kashima Jumpei, Kumagai Shogo, Horinouchi Hidehito, Ono Hanako, Shiraishi Kouya, Kohno Takashi, Kondo Shunsuke, Goto Yasushi, Yamamoto Noboru, Yatabe Yasushi, Hosomi Yukio, Kurata Takayasu, Naoki Katsuhiko, Suzuki Takuji, Ohe Yuichiro
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 12